CD274 and triple-negative breast carcinoma: In parallel, immunotherapy has become a first-line standard in metastatic triple-negative breast cancer: pembrolizumab-based regimens and atezolizumab combinations produce durable and clinically meaningful survival gains, particularly in PD-L1–positive tumors (Table S1) [50,51,52].